Illumina Ventures visions is to improve human health by unlocking the power of the genome.
Business Model:
Revenue: $0
Employees: 0-0
Address: 499 Illinois St Ste 210
City: San Francisco
State: CA
Zip: 94158
Country: US
Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world&s;s leading genomics solutions provider. They invest primarily in early stage companies, in areas where their expertise and special relationship with Illumina can add value. They typically syndicate with other leading institutional and strategic investors. Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2020 | Genome Medical | Series B | 0 |
10/2015 | 23andMe | Series E | 115M |
11/2020 | Rebus Bio | Series B | 20M |
1/2016 | Biota Technology | Venture Round | - |
9/2019 | Ribometrix | Equity | 7.8M |
1/2021 | Delfi Diagnostics | Series A | 0 |
5/2023 | Pluton Biosciences | Series A | 0 |
1/2016 | Desktop Genetics | Venture Round | - |
11/2021 | Arbor Biotechnologies | Series B | 0 |
12/2022 | Protillion Biosciences | Series A | 0 |
3/2018 | Cernostics | Series A | 2.5M |
11/2017 | NanoCellect Biomedical | Series B | 0 |
12/2018 | Kallyope | Series B | 21M |
8/2021 | NanoCellect Biomedical | Series D | 0 |
5/2017 | Genome Medical | Series A | 0 |
1/2018 | Genome Medical | Series A | 11M |
6/2019 | Encoded Therapeutics | Series C | 104M |
9/2021 | Walking Fish Therapeutics | Series A | 50M |
5/2018 | LunaDNA | Venture Round | 0 |
5/2019 | DNA Script | Series B | 38.5M |
6/2017 | Serimmune | Series A | 8M |
1/2018 | NanoCellect Biomedical | Venture Round | 250k |
11/2018 | Stilla Technologies | Series A | 18.3M |
5/2019 | LunaDNA | Venture Round | 4.6M |
2/2021 | NanoCellect Biomedical | Series C | 0 |
9/2021 | Alamar Biosciences | Series B | 80M |
4/2023 | Pattern Bioscience | Series D | 0 |
9/2022 | LetsGetChecked | Series D | 0 |
3/2022 | Sherlock Biosciences | Series B | 0 |
5/2020 | LetsGetChecked | Series C | 71M |
7/2020 | DNA Script | Series B | 50M |
12/2015 | Kallyope | Series A | 44M |
7/2019 | Cradle Genomics | Series A | 0 |
4/2023 | Pattern Bioscience | Series C | 0 |
3/2020 | Kallyope | Series C | 112M |
1/2020 | Fluent BioSciences | Series A | 0 |
12/2017 | LunaDNA | Seed Round | 2M |
4/2016 | Human Longevity | Series B | 220M |
9/2017 | DNA Script | Series A | 13.2M |
7/2020 | Pattern Bioscience | Series B | 9M |
2/2020 | Stilla Technologies | Series B | 0 |
12/2022 | SonoThera | Series A | 0 |
10/2021 | RedShift BioAnalytics | Series E | 20M |
8/2019 | Delfi Diagnostics | Seed Round | 5.5M |
10/2021 | DNA Script | Series C | 0 |
7/2022 | Delfi Diagnostics | Series B | 0 |
11/2018 | Ribometrix | Series A | 30M |
4/2020 | Actym Therapeutics, Inc. | Series A | 34M |
1/2016 | Twist Bioscience | Series D | 61M |
6/2021 | LetsGetChecked | Series D | 150M |
5/2019 | LunaPBC | Venture Round | 4.6M |
8/2021 | Genome Medical | Series C | 0 |
5/2020 | SQZ Biotech | Series D | 0 |
11/2021 | Stilla Technologies | Debt Financing | 0 |
2/2022 | Kallyope | Series D | 0 |
2/2018 | Kallyope | Series B | 66M |
7/2020 | Encoded Therapeutics | Series D | 0 |
8/2018 | SQZ Biotech | Series C | 0 |
5/2023 | Pluton Biosciences | Series A | 0 |
4/2023 | Pattern Bioscience | Series C | 0 |
12/2022 | Protillion Biosciences | Series A | 0 |
12/2022 | SonoThera | Series A | 0 |
9/2022 | LetsGetChecked | Series D | 0 |
7/2022 | Delfi Diagnostics | Series B | 0 |
3/2022 | Sherlock Biosciences | Series B | 0 |
2/2022 | Kallyope | Series D | 0 |
11/2021 | Stilla Technologies | Debt Financing | 0 |
11/2021 | Arbor Biotechnologies | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|